Fasinumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | HNGF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6406H9896N1700O2026S46 |
| Molar mass | 144618.27 g·mol−1 |
Fasinumab is a human monoclonal antibody designed for the treatment of acute sciatic pain.[1][2]
This drug was developed in collaboration by Teva Pharmaceutical Industries and Regeneron Pharmaceuticals.
It is currently at Phase III trials.
See also[]
- List of investigational analgesics
References[]
- ^ "Fasinumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
- ^ Tiseo PJ, Ren H, Mellis S (2014). "Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study". Journal of Pain Research. 7: 523–30. doi:10.2147/JPR.S65974. PMC 4155988. PMID 25210473.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by . |
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibody stubs
- Monoclonal antibodies